Polycystic ovarian syndrome: a curse to young women’s

Noopur Srivastava, Shashi Pratap Singh, Anurag Shukla, Kanchan Lata Gupta


The endocrine system is the group of glands that secrete hormone directly into the circulatory system moves towards distant target organs and affects them. This system release hormones that help control many important body functions. Dysfunctioning in the endocrine system may develop many disorders like diabetes, thyroid, growth disorders and sexual dysfunction. Poly cystic ovarian syndrome is one of the common endocrine disorder. PCOS is a common condition that causes a range of symptoms including irregular periods, unwanted hair growth, acne and weight problems. Increased circulating levels of testosterone can be considered as the major cause of development of polycystic ovarian syndrome. It is a male hormone, but women’s bodies make it too. Higher than normal testosterone level, makes women to experience PCOS. The physicians target on regular menstruation. In order to maintain the regular periods physicians basically administer Estrogen and Progesterone injection. Metformin is used during PCOS to treat insulin resistance developed in those women. Insulin resistance means that their bodies do not respond well to the hormone insulin that controls blood sugar levels. This causes blood sugar level to rise and this may lead to greater production of testosterone. Corticosteroids, vitamins, contraceptives pills are also prescribed for symptomatic treatment of PCOS. Changing of lifestyles may greatly help in management of poly cystic ovarian disorder. Regular exercise and weight management is the key for complete treatment of PCOS. This review contains all the information regarding PCOS.


Polycystic ovarian syndrome, Insulin sensitivity, Excess androgen production, Obesity, Hirustism, Acne, Infertility

Full Text:



Sturmhofel H, Bartke A. The endocrine system: an overview. Alcohol Health Res World. 1998;22(3):153-64.

Available at: http://www.webmd.com/ diabetes/endocrine-system-disorders#1. Accessed on 1 February 2018.

Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis.7 August 2003. BMJ. 2003;327(7421):951-3.

Zisser HC. Polycystic Ovary Syndrome and pregnancy: Is Metformin the Magic Bullet? Diabetes Spectrum. 2007;20(2):85-9.

Harrison TR. Harrison’s Principle of Internal Medicine. Edition-16th, McGrawHill; 2005: 275.

Macilwaine SC. What is a Disease? Br Med J. 1900;2(2085):1703-4.

Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ 2012;345:e8508.

Guyton AC, Hall JE. Textbook of Medical Phyisology. published by Elesevier Saunders. Edition: 11th; 2006: 974.

Available at: https://www.mayoclinic.org/ diseases-conditions/pcos/symptoms-causes/syc-20353439. Accessed on 3 February 2018.

Hayek EI S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly Cystic Ovarian Syndrome: An Update Overview. Front Physiol. 2016;7:124.

Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014;2(6):56.

Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89(3):505–22.

Available at: https://www.google.co.in/ search?q=pcos+and+pituitary+dysfunction&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjN1bnw_qHXAhUXSY8KHd_6CsAQ_AUICygC&biw=1092&bih=533#imgrc=3q9B42yD1K8mYM. Accessed on 2 February 2018.

Madnani N, Khan K, Chauhan P, Parmar G. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013;79:310-21.

Vellanki P. Polycystic Ovary Syndrome (PCOS) in Female Teenagers and Women: Endocrineweb.

Hart R. Polycystic ovarian syndrome–prognosis and treatment outcomes. Curr Opin Obstet Gynecol. 2007;19(6):529-35.

Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum C-Reactive protein (CRP) Levels and Insulin resistance in Non-Obese Women with Polycystic Ovarian Syndromeand Effect of Bicalutamide on Hirsutism, CRP Levels and Insulin Resistance. Horm. Res. 2004;62:283–7.

Vasan RS. Biomarkers of cardiovascular disease Molecular Basis and Practical Consideration. Circulation Aha Journals. Circulation. 2006;113:2335-2362.

Bruyneel A, Catteau-Jonard S, Decanter C, Clouqueur E, Tomaszewski C, Subtil D, et al. Polycystic ovary syndrome: what are the obstetrical risks? Gynecol Obstet Fertil. 2014;42(2):104-11.

Franks S. Diagnosis of Polycystic Ovary Syndrome: In Defense of the Rotterdam Criteria. J Clin Endocrinol Metabol. 2006;91(3):786-9.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–45.

Misso M, Boyle J, Norman R, Teede H. Development of evidenced-based guidelines for PCOS and implications for community health. Semin Reprod Med. 2014:32(3):230-40.

Williams T, Mortada R, Porter S. Diagnosis and Treatment Of Polycystic Ovary Syndrome. Am Fam Physician. 2016:94(2):106-13.

Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2011;17(2):171-83.

Redman LM, Elkind-Hirsch K, Ravussin E. Aerobic Exercise in women with polycystic ovary syndrome improves ovarian morphology independent of changes in body composition. Fertil Steril. 2011;95(8):2696–9.

Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-50.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin J.M, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England J Med. 2002:346(6):393-403.

Goodyear LJ, Kahn BB. Exercise, glucose transportand insulin sensitivity. Annu Rev Med. 1998;49;235-61.

Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol. 2006;22(5):235–8.

Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(9):4116–23.

Casper RF, Mitwally MFM. Aromatase Inhibitors for Ovulation Induction. The J Clin Endocrinol Metabol. 2006;91(3):760-71.

Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017;3(2):111–5.

Lumachi F, Rondinone R. Use of cyproterone acetate, finasterideand spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79(4):942–6.

Lee VC, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Cin Endocrinol (Oxf). 2011;74(5):537-46.

Casper F, Mitwally MF. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol. 2011;54(4):685–695.

Viola MI, Meyer D, Kruger T. Association between clomiphene citrate and visual disturbances with special emphasis on central retinal vein occlusion: a review. Gynecol Obstet Invest. 2011;71(2):73–6.

Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003;30(4 Suppl 14):3-11.

Tyagi S, Gupta P, Saini AS, Kaushal C and Sarma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various disease. J Adv Pharm Tehnol Res. 2011;2(4): 236-40.

Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, Patten SB. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76-85.

Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2013;98(12):4565-92.

Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.

Yildiz BO. Recent advances in the treatment of polycystic ovary syndrome. Expert Opin Investig Drugs. 2004;13(10):1295-305.

Junyoung Jo, Jae Lee Y, Lee H. Acupuncture for polycystic ovarian syndrome. Medicine (Baltimore). 2017;96(23):e7066.

Jedel E, Labrie F, Oden A, Nilsson L, Janson PO, Lind AK, et al. Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab. 2011;300(1):E37-45.

Pastore LM, Williams CD, Jenkins J, Patrie JT. True and sham acupuncture produced similar frequency of ovulation and improved LH to FSH ratios in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(10):3143-50.

Available at: https://www.sepalika.com/ pcos/natural-treatments-pcos-acne/. Accessed on 3 February 2018.

Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol. 2011:27(4):256–62.

Amini L, Tehranian N, Movahedin M, Ramezani Tehrani F, Ziaee S. Antioxidants and management of polycystic ovary syndrome in Iran: A systematic review of clinical trials. Iran J Reprod Med. 2015;13(1):1–8.

DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2018.03


  • There are currently no refbacks.

Copyright (c) 2018 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations